Cobimetinib

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma.[1][5] Cobimetinib is a MEK inhibitor.[1] Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech, a subsidiary of Roche.[1][5][6] The most common side effects include diarrhea, rash, nause... [wikipedia]